All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

EU approves Moderna's Spikevax, targeting LP.8.1 SARS-CoV-2, for coronavirus disease in patients from 6 months
Vaccine, infectious disease, mRNA vaccine, COVID-19, variant-specific, pediatric use - Read more

FDA approves Novo Nordisk's Alhemo®, TFPI-targeting therapy, for hemophilia A/B without inhibitors in Ph3 success
Monoclonal antibody, hemophilia, TFPI inhibitor, subcutaneous administration - Read more

FDA approves LENZ Therapeutics' VIZZ (aceclidine) eye drops for presbyopia in adults
Small molecule, ophthalmic, eye drops, presbyopia, age-related vision loss, miotic agent - Read more

THE GOOD
Business Development & Partnerships

NextCure seeks partners for NC605 antibody showing promise in brittle bone disease mouse models
Research collaboration, rare disease, antibody, R&D, licensing deal - Read more

Evotec sells French biosimilars facility to Sandoz for $300M, advancing asset-lighter manufacturing strategy
Manufacturing agreement, biosimilars, facility acquisition, biologics manufacturing, continuous manufacturing, milestone payments - Read more

MaxCyte, Anocca AB partner on TCR-T therapies; MaxCyte to receive licensing fees for electroporation platform technology
Licensing deal, cell therapy, oncology, manufacturing, T-cell therapy - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

ImmuneOnco reports promising Ph2 data for IMM2510, PD-L1xVEGF bispecific, in non-small cell lung cancer
Antibody, cancer, bispecific antibody, non-small cell lung cancer, PD-L1, VEGF, combination therapy - Read more

Soligenix's SGX945 demonstrates efficacy in Ph2 trial for Behçet's Disease, matching apremilast in oral ulcer treatment
Small molecule, autoimmune, Behçet's Disease, oral ulcers, dusquetide, rare disease - Read more

Eli Lilly's Ph3 data shows Kisunla maintains amyloid clearance in Alzheimer's disease patients after treatment discontinuation.
Antibody, neurological, monoclonal antibody, Alzheimer disease, amyloid plaque, disease progression - Read more

Eli Lilly's Mounjaro demonstrates heart health benefits in Ph3 trial for Type 2 diabetes patients
Small molecule, metabolic, GLP-1 receptor agonist, Type 2 diabetes, cardiovascular, obesity - Read more

THE GOOD
Earnings & Finances

Biogen raises sales outlook as Leqembi grows and awaits FDA decision on subcutaneous autoinjector option
Monoclonal antibody, Alzheimer's disease, financial, regulatory, commercial growth - Read more

Alnylam's rare disease drug Amvuttra smashes sales forecasts, boosting market cap above $50 billion
RNAi therapeutic, rare disease, financial, revenue impact - Read more

Biogen reports Leqembi sales growth of 58% globally as blood-based biomarker tests ease Alzheimer's treatment access
Monoclonal antibody, Alzheimer's disease, neurological, financial, strategic - Read more

AbbVie's Skyrizi and Rinvoq sales soar to $6.4B, expected to surpass Humira's peak revenue
Monoclonal antibody, autoimmune, financial, strategic, competitive - Read more

Sanofi CFO: Tariffs will have minimal financial impact in 2025 due to existing US inventory
Monoclonal antibody, autoimmune, financial, operational, regulatory - Read more

Sanofi's Q2 sales hit €10B ($11.43B) as Dupixent surges 21%, despite rising R&D expenses
Monoclonal antibody, autoimmune, financial, operational, R&D investment - Read more

THE GOOD
Fundraises

Frazier Life Sciences raises $1.3B venture fund for early-stage biotech investing and company creation
Venture capital, early-stage biotech, oncology, drug discovery, platform technology - Read more

Prime Medicine raises $125.4M public offering, advancing curative genetic therapies
Gene therapy, platform technology, genetic therapies, rare disease, cystic fibrosis, preclinical - Read more

Rein Therapeutics raises $21M flexible financing to advance pulmonary fibrosis clinical trials
Pulmonary disease, fibrosis, orphan indications, small molecule, clinical-stage - Read more

THE GOOD
Investments

PL BioScience expands headquarters to become world's largest Human Platelet Lysate producer with 20,000L capacity
Cell culture supplements, strategic, operational, manufacturing expansion, supply chain - Read more

THE GOOD
Mergers & Acquisitions

AbbVie reportedly pursuing $1B acquisition of Gilgamesh Pharmaceuticals to strengthen neuroscience portfolio amid strong earnings
Psychedelic compound, neuropsychiatry, strategic acquisition, portfolio expansion - Read more

ESTEVE acquires U.S.-based Regis Technologies, expanding American CDMO presence for small-molecule API development
Small molecule, CDMO, strategic acquisition, manufacturing capabilities, international expansion - Read more

THE GOOD
Regulatory

HHS launches pilot program testing drugmaker-managed rebates for 340B drugs starting 2026
Healthcare policy, drug pricing, operational, regulatory, financial - Read more

Prasad's FDA departure signals potential shift towards looser cell and gene therapy regulation
Cell and gene therapy, regulatory, policy shift, political impact - Read more

THE BAD
Clinical Trials

Nuvectis discontinues Ph1b GCN2 kinase activator NXP800 for ovarian cancer after limited efficacy data
Small molecule, cancer, kinase inhibitor, ovarian cancer, clinical trial failure, ARID1a mutation - Read more

AbbVie's lutikizumab fails Ph2 trial in ulcerative colitis, missing efficacy targets as IL-1 monotherapy
Protein therapy, autoimmune, monoclonal antibody, inflammatory bowel disease, IL-1 inhibitor, combination therapy - Read more

THE BAD
Earnings & Finances

Bristol Myers Squibb's Cobenfy future uncertain after Phase III failure; Alzheimer's psychosis trials ongoing
Small molecule, neurological, schizophrenia, Alzheimer's psychosis, regulatory, strategic - Read more

THE BAD
Layoffs

Merck & Co. slashes 6,000 jobs (8% of workforce) amid $3 billion cost-cutting initiative ahead of Keytruda biosimilar competition
Strategic, cost reduction, operational, financial - Read more

Moderna to cut 10% of workforce amid declining vaccine sales and cost-reduction efforts
mRNA vaccine, infectious disease, operational, cost reduction, financial - Read more

THE UGLY
Clinical Trials

FDA halts Allogene Therapeutics's ALLO-647 anti-CD52 antibody in Ph3 trial following patient death in large B-cell lymphoma
Cell therapy, cancer, CAR-T, large B-cell lymphoma, allogeneic, lymphodepletion - Read more

THE UGLY
Politics & Policy

Kennedy's CDC panel overhaul prompts ousted vaccine experts to call for alternative advisory system
Vaccines, infectious disease, regulatory, policy change - Read more

Trump threatens drugmakers with "every tool" if they don't lower US prices to international levels
Drug pricing, pharmaceutical policy, financial, regulatory, competitive - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here